Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | CCR5 | P51681 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506621 | 0.87 | OPRL1 (0.53) | OPRL1OPRM1OPRK1CCR5CCR3 | |
| SCHEMBL2450074 | 0.87 | CCR5 (0.51) | OPRL1OPRM1OPRK1CCR5 | |
| SCHEMBL2450324 | 0.85 | LTA4H (0.44) | OPRM1LTA4HKCNH2SIGMAR1 | |
| SCHEMBL2453225 | 0.85 | CCR5 (0.48) | OPRL1OPRM1OPRK1CCR5CCR3 | |
| SCHEMBL3509351 | 0.83 | CCR5 (0.58) | OPRL1OPRM1OPRK1CCR5 | |
| SCHEMBL3505476 | 0.82 | LTA4H (0.41) | OPRM1CCR5LTA4HKCNH2SIGMAR1 | |
| SCHEMBL2452290 | 0.78 | OPRL1 (0.45) | OPRL1OPRM1OPRK1CCR5 | |
| SCHEMBL2449653 | 0.78 | LTA4H (0.47) | OPRL1OPRM1OPRK1LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL2452777 | 0.78 | OPRL1 (0.44) | OPRL1OPRM1OPRK1CCR5 | |
| SCHEMBL2455582 | 0.78 | HRH3 (0.48) | OPRL1OPRM1OPRK1CCR5HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | OPRL1 390/4885OPRM1 436/4885OPRK1 282/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | OPRL1 390/4885OPRM1 436/4885OPRK1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.